The PETX HER2 trial results were a virtual blockbuster. Many of the patients (lol) have survived for several years beyond the expected OS, if I understand it correctly.
I believe researchers are well aware of the human applications for HER2 and the broader implications if it's successful treating canine osteosarcoma
And that is exactly what I believe Lombardo is betting on. Concentrate resources on AXAL and when PETX gets its approval....then HER2 will be put up for sale. Approval for canine, will increase the selling price. If AXAL gets EU approval, it my also make sense to sell the license agreement with PetX. Sell the future revenue stream from royalties along with HER2. The buyer and seller both win (and shareholders too).
News 
Market Data 
Discover 
